Are you over 18 and want to see adult content?
3
More Annotations
2
2
Favourite Annotations
![A complete backup of www.epochtimes.com/b5/20/2/7/n11850484.htm](https://www.archivebay.com/archive2/efbed526-0145-4f4f-85c6-7e682a794617.png)
A complete backup of www.epochtimes.com/b5/20/2/7/n11850484.htm
www.epochtimes.com/b5/20/2/7/n11850484.htm
Are you over 18 and want to see adult content?
![A complete backup of www.kicker.de/4589127/spielbericht](https://www.archivebay.com/archive2/3bba0cde-514e-49f6-987c-307968dcbc9e.png)
A complete backup of www.kicker.de/4589127/spielbericht
www.kicker.de/4589127/spielbericht
Are you over 18 and want to see adult content?
1
4
Text
EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences in
Europe.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
LATEST NEWS
European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the EuropeanUnion
JANSSEN PRESENTS ONE-SHOT COVID-19 VACCINE DATA Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine shot of 5 x 10 10 virus particles, according to a medRxiv preprint, now updated in the New England Journal of Medicine.This means that the vaccine, that is expected to be ready for EMA assessment in April 2021 might be given as single dose VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behind demand. COVAX: PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF Pfizer Inc. and Biontech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. CYTELL™ CELL IMAGING SYSTEM Cytell™ Cell Imaging System is an intuitive benchtop instrument equipped with on-board data analysis and visualisation tools. It streamlines and simplifies routine assays such as cell cycle and cell viability and efficiently delivers high quality, quantitative results. Key to the simplification are the on-board Bioapps; pre-configured,easy
FOCUS ON EURONEXT: THE LIFE SCIENCE LEADER Euronext is the largest Life Science stock market in Europe. During the 2013–2017 period, 48% of the 418 European Life Science companies which listed on markets decided to list their shares on Euronext. Capital raised via IPOs and follow-on financings on Euronext by European Life Science companies since 2013 amounts to €8.6bn. FDA GRANTS APPROVAL FOR ALZHEIMER’S DISEASE TREATMENT The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) by Biogen Inc., the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque, the company announced. IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. ROBERT PHILLIPS & RUDI BALLING: THE BUMPY ROAD TO Antibiotic resistance is widespread. Its global human and economic burden is tremendous and constantly MORE EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
LATEST NEWS
European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the EuropeanUnion
JANSSEN PRESENTS ONE-SHOT COVID-19 VACCINE DATA Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine shot of 5 x 10 10 virus particles, according to a medRxiv preprint, now updated in the New England Journal of Medicine.This means that the vaccine, that is expected to be ready for EMA assessment in April 2021 might be given as single dose VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behind demand. COVAX: PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF 1 day ago · Pfizer Inc. and Biontech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. CYTELL™ CELL IMAGING SYSTEM Cytell™ Cell Imaging System is an intuitive benchtop instrument equipped with on-board data analysis and visualisation tools. It streamlines and simplifies routine assays such as cell cycle and cell viability and efficiently delivers high quality, quantitative results. Key to the simplification are the on-board Bioapps; pre-configured,easy
FOCUS ON EURONEXT: THE LIFE SCIENCE LEADER Euronext is the largest Life Science stock market in Europe. During the 2013–2017 period, 48% of the 418 European Life Science companies which listed on markets decided to list their shares on Euronext. Capital raised via IPOs and follow-on financings on Euronext by European Life Science companies since 2013 amounts to €8.6bn. FDA GRANTS APPROVAL FOR ALZHEIMER’S DISEASE TREATMENT The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) by Biogen Inc., the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque, the company announced. IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. ROBERT PHILLIPS & RUDI BALLING: THE BUMPY ROAD TO Antibiotic resistance is widespread. Its global human and economic burden is tremendous and constantly MORE EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
BOEHRINGER INGELHEIM STARTS GENE THERAPY COLLABORATION FOR Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London, and from gene therapy developer and manufacturer Oxford Biomedica and will collaborate in R&D with the UK Cystic Fibrosis Gene Therapy Consortium, which has a clinical track record of six successful early stage CF gene therapies and has NOVO NORDISK REVEALS DETAILS ABOUT ITS R&D TRANSFORMATION Novo Nordisk reveals details about its R&D transformation. Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China. The job cuts will affect all R&D divisions. Then again, the company plansto establish
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
COVID-19 THERAPEUTICS: GERMANY LAUNCHES €300M FUNDING 13.05.2021. by tg. German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient's bedside. The announcement of German Health Minister Jens Spahn and federal Research Minister Anja Karliczek came one week after the European Commission issued a light version of the $10bn USprogramme
LATEST NEWS
European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the EuropeanUnion
JANSSEN PRESENTS ONE-SHOT COVID-19 VACCINE DATA Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine shot of 5 x 10 10 virus particles, according to a medRxiv preprint, now updated in the New England Journal of Medicine.This means that the vaccine, that is expected to be ready for EMA assessment in April 2021 might be given as single dose VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behind demand. COVAX: PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF 1 day ago · Pfizer Inc. and Biontech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. CYTELL™ CELL IMAGING SYSTEM Cytell™ Cell Imaging System is an intuitive benchtop instrument equipped with on-board data analysis and visualisation tools. It streamlines and simplifies routine assays such as cell cycle and cell viability and efficiently delivers high quality, quantitative results. Key to the simplification are the on-board Bioapps; pre-configured,easy
FDA GRANTS APPROVAL FOR ALZHEIMER’S DISEASE TREATMENT The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) by Biogen Inc., the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque, the company announced. IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. ROBERT PHILLIPS & RUDI BALLING: THE BUMPY ROAD TO Antibiotic resistance is widespread. Its global human and economic burden is tremendous and constantly MORE EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
JANSSEN PRESENTS ONE-SHOT COVID-19 VACCINE DATA Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine shot of 5 x 10 10 virus particles, according to a medRxiv preprint, now updated in the New England Journal of Medicine.This means that the vaccine, that is expected to be ready for EMA assessment in April 2021 might be given as single dose COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
COVID-19 THERAPEUTICS: GERMANY LAUNCHES €300M FUNDING 13.05.2021. by tg. German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient's bedside. The announcement of German Health Minister Jens Spahn and federal Research Minister Anja Karliczek came one week after the European Commission issued a light version of the $10bn USprogramme
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the FOCUS ON EURONEXT: THE LIFE SCIENCE LEADER Euronext is the largest Life Science stock market in Europe. During the 2013–2017 period, 48% of the 418 European Life Science companies which listed on markets decided to list their shares on Euronext. Capital raised via IPOs and follow-on financings on Euronext by European Life Science companies since 2013 amounts to €8.6bn. ROCHE IN TAKE-OVER DEAL WITH GENMARK DIAGNOSTICS Roche in take-over deal with GenMark Diagnostics. Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample. The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s unaffected closing BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbH EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
JANSSEN PRESENTS ONE-SHOT COVID-19 VACCINE DATA Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine shot of 5 x 10 10 virus particles, according to a medRxiv preprint, now updated in the New England Journal of Medicine.This means that the vaccine, that is expected to be ready for EMA assessment in April 2021 might be given as single dose COVID-19 MED APN01 SELECTED TO BE TESTED IN ACTIV STUDY 20.05.2021. by tg. APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds. Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS trial,which
COVID-19 THERAPEUTICS: GERMANY LAUNCHES €300M FUNDING 13.05.2021. by tg. German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient's bedside. The announcement of German Health Minister Jens Spahn and federal Research Minister Anja Karliczek came one week after the European Commission issued a light version of the $10bn USprogramme
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
GREEN LIGHT FOR THE CIRCULAR BIO-BASED EUROPE JOINT Green light for the Circular Bio-based Europe Joint Undertaking. The EC has agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted at the end of February 2021. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the FOCUS ON EURONEXT: THE LIFE SCIENCE LEADER Euronext is the largest Life Science stock market in Europe. During the 2013–2017 period, 48% of the 418 European Life Science companies which listed on markets decided to list their shares on Euronext. Capital raised via IPOs and follow-on financings on Euronext by European Life Science companies since 2013 amounts to €8.6bn. ROCHE IN TAKE-OVER DEAL WITH GENMARK DIAGNOSTICS Roche in take-over deal with GenMark Diagnostics. Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample. The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s unaffected closing BIO-BASED BUILDING BLOCKS AND POLYMERS Imprint Bio-based Building Blocks and Polymers – Global Capacities, Production and Trends 2018 – 2023 Publisher Michael Carus (V.i.S.d.P.) nova-Institut GmbHLATEST NEWS
European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the EuropeanUnion
COVID-19: SOLNATIDE APPROVED FOR COMPASSIONATE USE According to Bernhard Fischer, Managing Director of Vienna-based Apeptico, "this is the first compassionate use approval of an innovative drug from Austria for the treatment of SARS-CoV-2-induced acute pulmonary dysfunction (ARDS) in mechanically ventilated COVID-19 patients", who have reached disease stage 6 and 7 on the WHO diseasescale.
RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The researchers applied a technique to reconstruct language prehistory to analyse the spread of the SARS-CoV-2 virus. Comparative analyses of character-based phylogenetic networks suggest that all genomes are closely related and under evolutionary selection in their human hosts, sometimes with parallel evolution events, that is, the same virus SWISS BIOTECH DAY 2021 The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and is a fixed date in the community's calendar. While the event could not take place in 2020 due to the worldwide COVID-19 pandemic, we plan to bring the Swiss Biotech Day back on stage on September 7, 2021. COVAX: PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF 7 hours ago · Pfizer Inc. and Biontech SE announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE 1 day ago · In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behinddemand.
INCLUDING CHINA IN YOUR GLOBAL DRUG DEVELOPMENT STRATEGY 1 day ago · The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies? MEDICAL CANNABIS IN EUROPE The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term future outlook. FORMULATION DEVELOPMENT FOR ATMPS IN HIGH DEMAND 1 day ago · Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP FDA GRANTS APPROVAL FOR ALZHEIMER’S DISEASE TREATMENT 1 day ago · The U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) by Biogen Inc., the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque, the company announced. EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The researchers applied a technique to reconstruct language prehistory to analyse the spread of the SARS-CoV-2 virus. Comparative analyses of character-based phylogenetic networks suggest that all genomes are closely related and under evolutionary selection in their human hosts, sometimes with parallel evolution events, that is, the same virus GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO 11.05.2017. by tg. A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). Monthly eye injections of Avastin (bevacizumab) at US$60 per dose are as effective IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION 25.10.2017. by ml. Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH. Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The researchers applied a technique to reconstruct language prehistory to analyse the spread of the SARS-CoV-2 virus. Comparative analyses of character-based phylogenetic networks suggest that all genomes are closely related and under evolutionary selection in their human hosts, sometimes with parallel evolution events, that is, the same virus GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO 11.05.2017. by tg. A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). Monthly eye injections of Avastin (bevacizumab) at US$60 per dose are as effective IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION 25.10.2017. by ml. Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH. Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial 2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE 9 hours ago · In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behinddemand.
PROVIDING ACCESS TO COVID-19 MEDICINES AND VACCINES IP U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents: President Joe Biden in May threw his support behind waiving intellectual property rights for COVID-19 vaccines – very much to the surprise of the biotech world. FORMULATION DEVELOPMENT FOR ATMPS IN HIGH DEMAND 9 hours ago · Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands itsATMP
MEDICAL CANNABIS IN EUROPE 1 day ago · The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term futureoutlook.
EU REJECTS AMENDMENT 171 The EU parliament officially withdrew Amendment 171 from the table – a bill that would have banned plant-free dairy companies from using words like “buttery” or IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND 1 day ago · UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. GERMAN SYNBIO START-UP RAISES $15M FINANCING Origin.Bio, a new German synthetic biology company founded by former AMSilk-CEO Jens Klein, has raised $15m funding round led by EQTVentures.
CURRENT EU GMO LEGISLATION IS NOT FIT FOR PURPOSE The Commission study on Novel Genomic Techniques (NGTs) underlines that plants resulting from NGTs have the potential to contribute to a more sustainable food system and support the objectives of the European Green Deal and the Farm to Fork Strategy. At the same time, the study finds that the current GMO legislation, adopted in 2001, is not fit for purpose for these innovative technologies. EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The researchers applied a technique to reconstruct language prehistory to analyse the spread of the SARS-CoV-2 virus. Comparative analyses of character-based phylogenetic networks suggest that all genomes are closely related and under evolutionary selection in their human hosts, sometimes with parallel evolution events, that is, the same virus GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO 11.05.2017. by tg. A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). Monthly eye injections of Avastin (bevacizumab) at US$60 per dose are as effective IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION 25.10.2017. by ml. Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH. Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION Janssen to pledge COVID-19 vaccine to African Union. Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT). The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500million
RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The researchers applied a technique to reconstruct language prehistory to analyse the spread of the SARS-CoV-2 virus. Comparative analyses of character-based phylogenetic networks suggest that all genomes are closely related and under evolutionary selection in their human hosts, sometimes with parallel evolution events, that is, the same virus GALECTO RAISE US$85M IN NASDAQ IPO 30.10.2020by tg. HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of US$15 per share in the mid-point of itsrange from
SETTING TRENDS WITH ECO-FASHION The subsidiary of Circular Systems SPC has invented a closed-loop system that takes by-products from crops like oil-seed flax, hemp, sugarcane, bananas and pineapples and turns them into a biological fibre that can be used to make textiles. Driven by the trend towards sustainable fashion, more and more biotech start-ups are now turningto the
AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET AZ withdraws lung cancer drug from EU lead market. After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest oflung cancer
CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO 11.05.2017. by tg. A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). Monthly eye injections of Avastin (bevacizumab) at US$60 per dose are as effective IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION 25.10.2017. by ml. Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH. Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial 2021 - EUROPEAN BIOTECHNOLOGY Bioeconomy. those are among the ambitious goals of the €95.5bn Horizon Europe innovation programme approved by the European Council in early May. The means to these ends include new public-private partnerships for life sciences and biotech companies. A €10bn EIB financing tool is additionally available to drive the biologisation ofindustry
EURO BIOTECH GUIDE
The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 192 colored pages, the guide contains a short report about the currentgrowth in the EU
VARIANTS WILL DRIVE LONG-TERM COVID-19 VACCINE 4 hours ago · In an incredible feat of science, accelerated R&D within the space of a year has yielded 11 Covid-19 vaccines. As some countries now reach coverage of priority groups we are starting to see reductions in cases, hospitalisations and mortality, however, these countries remain the exception as global supply still lags far behinddemand.
PROVIDING ACCESS TO COVID-19 MEDICINES AND VACCINES IP U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents: President Joe Biden in May threw his support behind waiving intellectual property rights for COVID-19 vaccines – very much to the surprise of the biotech world. FORMULATION DEVELOPMENT FOR ATMPS IN HIGH DEMAND 4 hours ago · Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands itsATMP
MEDICAL CANNABIS IN EUROPE 1 day ago · The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term futureoutlook.
EU REJECTS AMENDMENT 171 The EU parliament officially withdrew Amendment 171 from the table – a bill that would have banned plant-free dairy companies from using words like “buttery” or IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND 1 day ago · UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. GERMAN SYNBIO START-UP RAISES $15M FINANCING Origin.Bio, a new German synthetic biology company founded by former AMSilk-CEO Jens Klein, has raised $15m funding round led by EQTVentures.
CURRENT EU GMO LEGISLATION IS NOT FIT FOR PURPOSE The Commission study on Novel Genomic Techniques (NGTs) underlines that plants resulting from NGTs have the potential to contribute to a more sustainable food system and support the objectives of the European Green Deal and the Farm to Fork Strategy. At the same time, the study finds that the current GMO legislation, adopted in 2001, is not fit for purpose for these innovative technologies. EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY The COVID-19 pandemic has dramatically boosted demand for GMP-compliantly manufactured plasmids and viral vectors for vaccine production, and CDMOs and other developers are racing to expand production capacities.EURO BIOTECH GUIDE
European Biotechnology Science & Industry Guide. Championing scientific diversity in Europe! The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral one-shot vaccine through its COVAX facility to poor Africancountries.
SETTING TRENDS WITH ECO-FASHION Back in July 2017, one of the world’s ecological fashion icons made a strong commitment to biotech. “This is truly a moment to celebrate technology and the future of fashion,” British designer Stella McCartney said when she signed an agreement for her collection with Bolt Threads Inc, a producer of biotech-made silk. QIAGEN/ILLUMINA: EARTHQUAKE IN NGS IVD MARKET The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower than the Refinitiv consensus estimate for US$887.9m). CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). GALECTO RAISE US$85M IN NASDAQ IPO The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a shareprice of US$15
IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria – including multi-resistant strains – AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the EUROPEAN BIOTECHNOLOGY For almost two decades, European Biotechnology has been the first and foremost information platform reporting on the life sciences inEurope.
2021 - EUROPEAN BIOTECHNOLOGY The COVID-19 pandemic has dramatically boosted demand for GMP-compliantly manufactured plasmids and viral vectors for vaccine production, and CDMOs and other developers are racing to expand production capacities.EURO BIOTECH GUIDE
European Biotechnology Science & Industry Guide. Championing scientific diversity in Europe! The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. JANSSEN TO PLEDGE COVID-19 VACCINE TO AFRICAN UNION The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral one-shot vaccine through its COVAX facility to poor Africancountries.
SETTING TRENDS WITH ECO-FASHION Back in July 2017, one of the world’s ecological fashion icons made a strong commitment to biotech. “This is truly a moment to celebrate technology and the future of fashion,” British designer Stella McCartney said when she signed an agreement for her collection with Bolt Threads Inc, a producer of biotech-made silk. QIAGEN/ILLUMINA: EARTHQUAKE IN NGS IVD MARKET The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower than the Refinitiv consensus estimate for US$887.9m). CHEAP AVASTIN AS EFFECTIVE AS EYLEA IN CRVO A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO). GALECTO RAISE US$85M IN NASDAQ IPO The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a shareprice of US$15
IMMUNETHEP RECEIVES GRANT FROM GATES FOUNDATION Immunethep did not disclose any details about the grant. The biotech company based in Cantanhede is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria – including multi-resistant strains – AZ WITHDRAWS LUNG CANCER DRUG FROM EU LEAD MARKET After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses theEURO BIOTECH GUIDE
European Biotechnology Science & Industry Guide. Championing scientific diversity in Europe! The 11th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. NEWS - EUROPEAN BIOTECHNOLOGY European Biotechnology reports in English on political, economic and technical development, covering the life sciences in the EuropeanUnion
COVID-19: SOLNATIDE APPROVED FOR COMPASSIONATE USE The more COVID-19 patients reach advanced disease stages according to the eight-level WHO disease scale, the more important it becomes to treat life-threatening respiratory distress syndrome (ARDS) or pulmonary edema.Respiratory disease specialist Apeptico Forschung und Entwicklung GmbH has now received compassionate use approval from the Austrian Federal Office for Safety in Health PROVIDING ACCESS TO COVID-19 MEDICINES AND VACCINES IP U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents: President Joe Biden in May threw his support behind waiving intellectual property rights for COVID-19 vaccines – very much to the surprise of the biotech world. RESEARCHERS RECONSTRUCT SARS-COV-2 EVOLUTION The work published by Peter Forster and collegues from University Cambridge in PNAS is based on a phylogenetic network of the about almost completely sequenced 160 SARS-CoV-2 genomes sampled from across the world and stored in the GISAID database, which contained a compilation of 253 severe SARS-CoV-2 genomes. The researchers applied a technique to reconstruct language prehistory to MEDICAL CANNABIS IN EUROPE 6 hours ago · The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author Marguerite Arnold to give a long-term futureoutlook.
CURRENT EU GMO LEGISLATION IS NOT FIT FOR PURPOSE The Commission study on Novel Genomic Techniques (NGTs) underlines that plants resulting from NGTs have the potential to contribute to a more sustainable food system and support the objectives of the European Green Deal and the Farm to Fork Strategy. At the same time, the study finds that the current GMO legislation, adopted in 2001, is not fit for purpose for these innovative technologies. B MEDICAL SYSTEMS' RELIABLE ULTRA-LOW FREEZERS Ultra-low freezers, or ULTs, are specialised refrige-rating equipment created to store vaccines, medicines, and samples at ultra-low temperatures. By offering storage temperatures ranging from -20°C to -86°C and energy efficiency, B Medical Systems’ ULTs create an ideal environment for the long-term storage of extremely temperature-sensitive biologicals, making its products perfect for use IKSUDA THERAPEUTICS CLOSES $47M FINANCING ROUND 16 hours ago · UK-based Iksuda Therapeutics (Iksuda), a developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, announced it has completed a US $47m financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. LONZA EXPANDS EU PRODUCTION CAPACITY FOR MODERNA VACCINE Lonza will expand its production capacity of Moderna’s mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands. Ihr Browser unterstützt leider kein JavaScript. Ohne JavaScript können diese Seiten nicht ordentlich dargestellt werden.* RSS
* CONTACT US
* EDITORIAL TEAM
* ADVERTISING
* ASSOCIATIONS
* BIOCOM AG
* UP TO DATE
* LATEST NEWS
* BACKGROUNDS & STORIES* APPOINTMENTS
* COVID-19
* OPINION
* EVENTS
* EFIB 2020 Sustainability Dialogue* HIGHLIGHTS
* THE MAG
* ISSUES
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* SPECIAL
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* SUBSCRIBE
* Euro Biotech Guide* SERVICE
* Financial markets
* Job market
* PRODUCTS
* SPONSORED PUBLICATIONS* Advertise
* Newsletter
* Contact Us
* __
* UP TO DATE
* LATEST NEWS
* BACKGROUNDS & STORIES* APPOINTMENTS
* COVID-19
* OPINION
* EVENTS
* EFIB 2020 Sustainability Dialogue* HIGHLIGHTS
* THE MAG
* ISSUES
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* SPECIAL
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* SUBSCRIBE
* Euro Biotech Guide* SERVICE
* Financial markets
* Job market
* PRODUCTS
* SPONSORED PUBLICATIONS* Advertise
* Newsletter
* Contact Us
* SEARCH
* RSS
* CONTACT US
* EDITORIAL TEAM
* ADVERTISING
* ASSOCIATIONS
* BIOCOM AG
__LATEST NEWS
UK APPROVES BIONTECH/PFIZER COVID-19 VACCINE Biontech and Pfizer have received emergency approval for their COVID-19 vaccine in the UK. Mass immunization could start...MORE
GERMANY FIRST EU COUNTRY TO LAUNCH COVID-19... After months of lobbying by the BIOM biotech cluster, Bavaria is launching a €50m initiative to push the best and...MORE
MODERNA TO FILE FOR EU APPROVAL OF MRNA-1273... COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on...MORE
SWISS NOEMA PHARMA RAISES CHF54M IN SERIES A... Noema Pharma AG kicks off with CHF54m and licenced drug candidatesfrom Roche AG.
MORE
DRUG SET TO RESCUE COVID-19 PATIENTS AT ICUS Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill...MORE
SIGN UP FOR OUR FREE NEWSLETTER Your e-mail-address is already registered. Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter. A transfer of the data to third parties will not occur. For further information, please refer to our privacy policy.
__BACKGROUND
WHAT’S IN A PATENT? IP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the...MORE
__SERVICE
Advertorial 25.11.2020 STARTUP LABS AT THE VIENNA BIOCENTER The Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in...MORE
Advertorial
A COMPREHENSIVE TOOLSET FOR COVID-19 RESEARCH Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19...MORE
__THE MAG
Current issue
THE VOID – COVID-19-THERAPEUTICS A licensed vaccine for COVID-19 could soon be a reality, but therapy options remain limited, while deaths in the ongoing pandemic continueto mount...
Special
GUIDE TO LIFE SCIENCES EVENTS The EuroBioFairs Compass shows you which conference, trade fair, or partnering show to mark on your event calender. We very much hope thatwith the...
SPECIALS SEE ALL
Previous
Next
__PEOPLE
APPOINTMENTS
MANAGEMENT CHANGES AT BIOCHEK NEW DIRECTOR GENERAL OF EUROPABIO ELRIG – KEEPING CONNECTEDOPINION
HARMONISATION OF PATENT LAW WITHOUT THE UPC? WOMEN'S HEALTH FROM NICHE TO MAINSTREAM URGENT NEED FOR MEDICAL DATA NETWORK ACROSS BORDERS__ Contact us
__ Advertise with us__ RSS
__EVENTS
EVENT HIGHLIGHT 07.12.2020 NEW DATE & PLACE: MEDFIT AND BIOFIT 2020 The BIoFIT event and MedFIT event will be held December 7-8 in Lille, France. In the unique context of this year, and to answer the organisation challenges we are facing, MedFIT...MORE
EVENT RECOMMENDATION 18.05.2021 A NEW ERA BEGINS: THE RENEWABLE MATERIALS CONFERENCE,... Featuring a unique concept to present all sustainable and renewable material solutions at one event, 18-20 May 2021: bio-based, CO2-based and recycled - at the Renewable Materials...MORE
UPCOMING EVENTS
BIOFIT 2020
07.12. - 08.12.2020 ǀ +++ online +++PHARMA OUTSOURCING
10.12.2020 ǀ +++ online +++ GLOBAL FORUM FOR FOOD AND AGRICULTURE – GFFA 2021 18.01. - 22.01.2021 ǀ +++ online +++ ASIAPLX 1 – MARKETPLACE FOR PHARMA BUSINESS OPPORTUNITIES 25.01. - 26.01.2021 ǀ Singapore SEE ALLFREE NEWSLETTER
__SIGN UP FOR OUR FREE NEWSLETTER __SUBSCRIBE TO OUR MAGAZINE__ __ Free
Newsletter! __Always up to date! __All news at one glance! __All important events! Your e-mail-address is already registered. Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter. A transfer of the data to third parties will not occur. For further information, please refer to our privacy policy.
* UP TO DATE
* NEWS AND STORIES
* PEOPLE
* APPOINTMENTS
* OPINION
* EVENTS
* HIGHLIGHTS
* THE MAG
* ISSUES
* SPECIALS
* INSIDE
* SERVICE
* NEWSLETTER
* CONTACT US
* DATA SECURITY
* IMPRINT
SIGN UP FOR OUR FREE NEWSLETTER BIOCOM AG 2000 - 2020__ __ __
Details
4
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0